Suppression of Cavernosal Fibrosis in a Rat Model
- PMID: 29631978
- DOI: 10.1016/j.sxmr.2018.02.007
Suppression of Cavernosal Fibrosis in a Rat Model
Abstract
Introduction: Cavernosal fibrosis is an important pathologic condition leading to erectile dysfunction (ED). The etiologies of cavernosal fibrosis include aging, diabetes mellitus, castration, cavernosal nerve injury during radical prostatectomy, hypertension, and Peyronie disease.
Aims: To summarize published studies investigating suppression of cavernosal fibrosis in rat models of ED of various etiologies.
Methods: A literature search was conducted using PubMed. Relevant studies were identified using search terms such as erectile dysfunction, penis, fibrosis, and rat models.
Main outcome measures: We reviewed representative literature studies on the mechanisms and suppression of cavernosal fibrosis in rat models of ED.
Results: The underlying mechanisms and potential therapeutic strategies suggested thus far for cavernosal fibrosis in rat models of ED were as follows. For age-related ED involving oxidative stress and tumor growth factor-β1 (TGF-β1)-driven pathways such as RhoA-ROCK1-LIMK2-cofilin or p42-44 and mitogen-activated protein kinase, proposed therapeutic strategies included phosphodiesterase type 5 inhibitors (PDE5Is), kallikrein-kinin system stimulators, and calorie restriction. For diabetes-related ED involving angiotensin-II- and TGF-β1-driven Smad and non-Smad pathways, TGF-β1-Wnt10b, and histone deacetylase (HDAC)-TGF-β1 pathways, positive therapeutic results were obtained with PDE5Is, TGF-β1 antagonists, HDAC inhibitors, antioxidants, sphingosine-1-phosphate receptor modulators (fingolimod), angiotensin-II antagonists, stem cell therapy, and antidiabetic drugs. For cavernosal nerve injury-associated ED involving TGF-β1-driven pathways (Smad or RhoA-ROCK1-LIMK2-cofilin), Sonic hedgehog signaling, angiotensin-II-Smad, and HDAC4-TGF-β1-Smad signaling triggered by cavernosal hypoxia, PDE5Is, angiotensin-II antagonists, stem cell therapy, HDAC inhibitors, Sonic hedgehog administration, ROCK inhibitors, and LIMK2 inhibitors have shown positive results. For testosterone deficiency-associated ED, TGF-β1-driven pathways were found to be responsive to testosterone supplementation. For hypertensive ED, positive therapeutic results were obtained with angiotensin-II antagonists. For Peyronie disease involving TGF-β1 or myostatin signaling, proposed therapeutic strategies included intra-tunical injection of TGF-β receptor inhibitors or adipose tissue-derived stem cells and HDAC2 small hairpin RNA.
Conclusion: Several signaling pathways appear to be responsible for the development of cavernosal fibrosis related to ED of various etiologies. Some therapeutic success has been achieved in animal models, but further research focusing on mechanism-specific targeted therapies is needed. Cho MC, Song WH, Paick J-S. Suppression of Cavernosal Fibrosis in a Rat Model. Sex Med Rev 2018;6:572-582.
Keywords: Erectile Dysfunction; Fibrosis; Penis; Rat.
Copyright © 2018 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.
Similar articles
-
P144, A TGF-β1 antagonist peptide, synergizes with sildenafil and enhances erectile response via amelioration of cavernosal fibrosis in diabetic rats.J Sex Med. 2013 Dec;10(12):2942-51. doi: 10.1111/jsm.12325. Epub 2013 Oct 17. J Sex Med. 2013. PMID: 24134744
-
Chronic administration of LIMK2 inhibitors alleviates cavernosal veno-occlusive dysfunction through suppression of cavernosal fibrosis in a rat model of erectile dysfunction after cavernosal nerve injury.PLoS One. 2019 Mar 14;14(3):e0213586. doi: 10.1371/journal.pone.0213586. eCollection 2019. PLoS One. 2019. PMID: 30870492 Free PMC article.
-
Pathway analysis of microarray data from corpora cavernosal tissue of patients with a prostatectomy or Peyronie disease in comparison with a cavernous nerve-injured rat model of erectile dysfunction.J Sex Med. 2023 Feb 14;20(2):139-151. doi: 10.1093/jsxmed/qdac019. J Sex Med. 2023. PMID: 36763930 Free PMC article.
-
Cavernous smooth muscles: innovative potential therapies are promising for an unrevealed clinical diagnosis.Int Urol Nephrol. 2020 Feb;52(2):205-217. doi: 10.1007/s11255-019-02309-9. Epub 2019 Oct 15. Int Urol Nephrol. 2020. PMID: 31617065 Review.
-
A new strategy, SuperEnzyme gene therapy in penile rehabilitation.J Sex Med. 2009 Mar;6 Suppl 3:328-33. doi: 10.1111/j.1743-6109.2008.01191.x. J Sex Med. 2009. PMID: 19267856 Review.
Cited by
-
Nitro-oleic acid (NO2-OA) ameliorates erectile dysfunction in a rat model of diabetes mellitus via modulation of fibrosis, inflammation and autophagy.Transl Androl Urol. 2024 Apr 30;13(4):537-547. doi: 10.21037/tau-23-547. Epub 2024 Apr 9. Transl Androl Urol. 2024. PMID: 38721285 Free PMC article.
-
Downregulation of the expression of galanin impairs erectile function in hypoandrogenic rats.Sex Med. 2023 Jun 20;11(3):qfad029. doi: 10.1093/sexmed/qfad029. eCollection 2023 Jun. Sex Med. 2023. PMID: 37351545 Free PMC article.
-
Overexpression of PRDX2 in Adipose-Derived Mesenchymal Stem Cells Enhances the Therapeutic Effect in a Neurogenic Erectile Dysfunction Rat Model by Inhibiting Ferroptosis.Oxid Med Cell Longev. 2023 Feb 8;2023:4952857. doi: 10.1155/2023/4952857. eCollection 2023. Oxid Med Cell Longev. 2023. PMID: 36819780 Free PMC article.
-
Buyang Huanwu Decoction Ameliorates Damage of Erectile Tissue and Function Following Bilateral Cavernous Nerve Injury.Chin J Integr Med. 2023 Sep;29(9):791-800. doi: 10.1007/s11655-022-3532-9. Epub 2022 Jun 9. Chin J Integr Med. 2023. PMID: 35679003
-
Single-Cell RNA Sequencing of Human Corpus Cavernosum Reveals Cellular Heterogeneity Landscapes in Erectile Dysfunction.Front Endocrinol (Lausanne). 2022 Apr 20;13:874915. doi: 10.3389/fendo.2022.874915. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35518933 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical